Trade Alerts, Monday November 24, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Mon Nov 24th - #FRGT #MBRX #CLSD #CHR - More: crystalequityresearch.com/trade-alerts... - #smallcap

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Clearside Biomedical (Nasdaq: CLSD) filed a voluntary petition under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on November 24, 2025 (Case No. 25-12109) and intends to seek court authorization for a Section 363 auction and sale of its assets. The company says the structured process aims to maximize stakeholder value while normal operations continue under court supervision.Key assets for sale include the commercial SCS Microinjector platform and XIPERE, the Phase 3-ready CLS-AX program for wet AMD and diabetic retinopathy, IND-ready programs for GA and DME, and rights linked to a royalty sub with a $106.5M revenue cap. Advisors include Cooley, Richards Layton & Finger, and BRG.

#CLSD Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

www.stocktitan.net/news/CLSD/clearside-biom...

12 Health Care Stocks Moving In Friday's Pre-Market Session - bioAffinity Technologies (NASDAQ:BIAF), Clearside Biomedical (NASDAQ:CLSD) Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers bioAffinity Technologies (NASDAQ: BIAF ) stock increased by 71.8% to $5.86 during Friday's pre-market session. The compan...

#BIAF #BZI-TFM #CLSD #CRNX #DRIO #GUTS #MDCX #NLSP #ORGO #Penny #Stocks

Origin | Interest | Match

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress Clearside Biomedical (Nasdaq: CLSD) announced multiple presentations featuring its SCS Microinjector® platform at the upcoming 25th EURETINA Congress in Paris from September 4-7, 2025. The presentations will highlight the company's suprachoroidal delivery platform designed for treating various retinal diseases including wet AMD, diabetic retinopathy, and geographic atrophy.Key presentations include Phase 2b results from the ODYSSEY trial and Phase 3 program updates for CLS-AX in neovascular age-related macular degeneration, presented by Dr. Sobha Sivaprasad. Dr. Victor Chong, Chief Medical Officer, will present a decade-long review of suprachoroidal drug delivery evolution and participate in a panel discussion on geographic atrophy at the Ophthalmology Futures Retina Forum.

#CLSD Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

www.stocktitan.net/news/CLSD/clearside-biom...

BREAKING NEWS: ( NASDAQ: #CLSD ) Expected earnings - Clearside Biomedical Inc.

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks oversold with improving relative strength, Wed Jul 23rd - #ZVSA #MLAB #CLSD #FOXO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

News; ( NASDAQ: #CLSD ) Clearside Biomedical Announces Approval of XIPERE Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Breakthrough Eye Treatment XIPERE Secures Major Health Canada Approval for Macular Edema Health Canada approves XIPERE for uveitic macular edema treatment, expanding Clearside's global reach. Now approved in 4 major markets. See expansion details.

#CLSD Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with

#CLSD Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

www.stocktitan.net/news/CLSD/clearside-biom...

Literacy Crisis? How States Are Turning the Page Preparing, Implementing, and Sustaining Comprehensive Literacy Initiatives In education policy and practice, I would argue no area is as crucial as literacy. Literacy forms the foundation for all…

Resources alone don’t raise reading scores. Sustainable literacy gains come from strategic implementation: aligned frameworks, data use, and leadership capacity.
buff.ly/FvLxWYf #Literacy #Reading #ScienceOfReading #CLSD #MTSS #MTSSR

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting Clearside Biomedical (NASDAQ: CLSD) announced multiple upcoming presentations featuring its SCS Microinjector platform at the Clinical Trials at the Summit Meeting on June 21, 2025, in Las Vegas. The presentations will showcase the platform's versatility in delivering various eye therapies through the suprachoroidal space. Key presentations include updates on CLS-AX for nAMD Phase 3 program, suprachoroidal ABBV-RGX-314 for DR treatment, and Bel-sar for choroidal melanoma Phase 3 trial. Dr. Victor Chong, CMO and EVP, emphasized the platform's capability as an in-office solution for vision-preserving therapies, highlighting its benefits of extended durability and flexible dosing for retinal diseases.

#CLSD Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update Clearside Biomedical (NASDAQ: CLSD) reported Q1 2025 financial results and corporate updates. Key highlights include a successful End-of-Phase 2 FDA meeting for CLS-AX in wet AMD, targeting a flexible three-to-six-month dosing label. Q1 revenue was $2.3 million, up from $0.2M in Q1 2024, driven by partner milestone payments. Net loss decreased to $8.2 million ($0.11/share) from $11.8M ($0.17/share) year-over-year. The company's cash position stands at $13.6 million, expected to fund operations into Q4 2025. Notable partner progress includes ARCATUS® approvals in Australia and Singapore, and an NDA under review in China. BioCryst Pharmaceuticals received authorization to start clinical trials for avoralstat in Australia using Clearside's SCS Microinjector®.

#CLSD Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting Clearside Biomedical (NASDAQ: CLSD) showcased six presentations at the ARVO 2025 Meeting, highlighting their CLS-AX (axitinib injectable suspension) program and suprachoroidal drug delivery platform. The Phase 2b ODYSSEY trial for CLS-AX demonstrated positive results in treating wet AMD, maintaining stable vision while reducing injection frequency. Key developments include: Development of the first machine learning algorithm for imaging suprachoroidal space (SCS) drug delivery Creation of a novel force analysis method for drug-device optimization Over 15,000 completed injections in their clinically validated training program Successful Phase 2b results supporting CLS-AX as a potential safe and long-acting therapy The company's SCS Microinjector® technology positions Clearside as a leader in suprachoroidal drug delivery, offering a transformative approach to treating retinal diseases.

#CLSD Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial Q4 revenue falls to $0.3M, while FDA endorses Phase 3 plans for wet AMD treatment. Strategic partnerships advance despite widening losses. Full analysis inside.

#CLSD Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/CLSD/clearside-biom...

Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 New clinical data reveals promising results for CLS-AX in wet AMD treatment. Six studies validate suprachoroidal delivery platform's potential. Full analysis inside.

#CLSD Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit Clearside Biomedical (NASDAQ: CLSD) presented updates on its lead clinical program CLS-AX and suprachoroidal delivery platform at the 2025 Wet AMD & Diabetic Eye Disease Summit. The company showcased post-hoc analyses comparing rescue criteria and intervention-free rates for Tyrosine Kinase Inhibitors (TKIs) in wet AMD development.Chief Medical Officer Victor Chong highlighted the potential benefits of their SCS Microinjector® technology, which delivers therapies directly to the retina, macula, and choroid. The presentation emphasized CLS-AX's advantages in treating wet AMD, including pan-VEGF receptors blockage and extended drug delivery. The suprachoroidal approach shows potential safety benefits, including minimal risk of endophthalmitis and cataract.Following a successful End-of-Phase 2 meeting with the FDA, Clearside outlined Phase 3 trial plans targeting the $12+ billion wet AMD market. The company's strategy aligns with FDA's 2023 draft guidance, focusing on reducing treatment burden while maintaining visual acuity alongside anti-VEGF biologics flexibility.

#CLSD Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

www.stocktitan.net/news/CLSD/clearside-biom...

Breaking News: ( NASDAQ: #CLSD ) Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD Clearside Biomedical (NASDAQ: CLSD) has announced successful End-of-Phase 2 meeting results with the FDA regarding CLS-AX for wet AMD treatment. The company received alignment on its Phase 3 program design for two concurrent non-inferiority pivotal trials.The proposed Phase 3 trials will feature:~450 treatment-naïve participants per trial (225 per arm)Comparison of CLS-AX (1 mg) to aflibercept (2 mg)Primary endpoint measuring average BCVA change from baseline at Week 52Flexible maintenance dosing of every 3 to 6 monthsCLS-AX combines flexible dosing of a biologic with extended duration of a tyrosine kinase inhibitor, administered via suprachoroidal injection. The treatment targets the $12+ billion wet AMD market, offering potential advantages through its positive safety profile, extended duration, and proven re-dosing capability.

#CLSD Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients Phase 2b trial reveals promising durability data for CLS-AX in wet AMD treatment, with two-thirds of patients maintaining stability without rescue therapy for 6 months.

#CLSD Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

www.stocktitan.net/news/CLSD/clearside-biom...

Revolutionary Eye Treatment Could Replace Monthly Injections for AMD Patients Clearside Biomedical's suprachoroidal CLS-AX demonstrates 6-month durability in wet AMD treatment, offering flexible dosing and enhanced safety through precise retinal delivery technology.

#CLSD Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside's ARCATUS Eye Treatment Wins Historic First Approvals in Australia, Singapore Clearside Biomedical's partner Arctic Vision secures landmark approvals for ARCATUS, the world's first suprachoroidal therapy for uveitic macular edema treatment.

#CLSD Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

www.stocktitan.net/news/CLSD/clearside-biom...

Clearside Biomedical Unveils Groundbreaking Insights on Retinal Drug Development in Eye Journal Leading ophthalmology expert Dr. Victor Chong shares critical perspectives on clinical trial design and regulatory pathways for retinal disease treatments in prestigious publication.

#CLSD Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

www.stocktitan.net/news/CLSD/clearside-biom...

#CLSD Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

www.stocktitan.net/news/CLSD/clearside-biom...

JUST IN: ( NASDAQ: #CLSD ) Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

#StockMarket #News

🚀 Invista no futuro com a NovaDAX! 💰 Negocie criptomoedas de forma simples, segura e rápida. Ganhe bônus convidando seus amigos e comece sua jornada no mercado cripto agora!
#NovaDAX
#Criptomoedas
#VLY
#NOV
#SLSR
#CLSD
#DEI
#OptionFlow
#OptionsTrading
#Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VLY, #NOV, #SLSR, #CLSD, #DEI

#OptionFlow #OptionsTrading #Trading

News; ( NASDAQ: #CLSD ) Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

#StockMarket #News